Composite fiber structures with antiproliferative agents exhibit advantageous drug delivery and cell growth inhibition in vitro

Journal of Pharmaceutical Sciences

Volumn 100, Issue 1, 2011, Pages 133-149

  Kraitzer, Amir ^a   Kloog, Yoel ^a   Haklai, Roni ^a   Zilberman, Meital ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Drug eluting fibers; Drug eluting stents; Farnesylthiosalicylate (FTS); Local cancer treatment; Paclitaxel

Indexed keywords

FARNESYLTHIOSALICYLIC ACID; MAXON; PACLITAXEL; POLYGLACTIN; SALIRASIB; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CELL DEATH; COMPOSITE MATERIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; FIBER; FREEZE DRYING; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; RAT;

EID: 78650037285     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22238     Document Type: Article

References (32)

1. Feng S, Huang G. 2001. Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers. J Control Release 71: 53-69.
2. Dhanikula AB, Panchagnula R. 1999. Localized paclitaxel delivery. Int J Pharm 183: 85-100.
3. Silber S, Grudel E. 2001. The Boston Scientific antipropliferative, Paclitaxel eluting stent (TAXUS). In: Serruys PW, Rensing BJ, editors. Handbook of coronary stents. London: Martin Dunitz. pp 311-319.
4. Farb A, Heller PF, Shroff S, Cheng L, Kolodgie FD, Carter AJ, Scott DS, Froehlich J, Virmani R. 2001. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 104: 473-479.
5. Marom M, Haklai R, Ben-Baruch G, Marciano D, Egozi Y, Kloog Y. 1995. Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid. J Biol Chem 270: 22263-22270.
6. George J, Sack J, Barshack I, Keren P, Goldberg I, Haklai R, Elad-Sfadia G, Kloog Y, Keren G. 2004. Inhibition of intimal thickening in the rat carotid artery injury model by a nontoxic Ras inhibitor. Arterioscler Thromb Vasc Biol 24: 363-368.
7. Kloog Y, Cox AD. 2004. Prenyl-binding domains: Potential targets for Ras inhibitors and anti-cancer drugs. Semin Cancer Biol 14: 253-261.
8. Heldman AW, Cheng L, Jenkins GM, Heller PF, Kim DW, Ware M, Jr., Nater C, Hruban RH, Rezai B, Abella BS, Bunge KE, Kinsella JL, Sollott SJ, Lakatta EG, Brinker JA, Hunter WL, Froehlich JP. 2001. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 103: 2289-2295.
9. Venkatraman S, Boey F. 2007. Release profiles in drug-eluting stents: Issues and uncertainties. J Control Release 120: 149-160.
10. Commandeur S, van Beusekom HM, van der Giessen WJ. 2006. Polymers, drug release, and drug-eluting stents. J Interv Cardiol 19: 500-506.
11. Goldberg L, Kloog Y. 2006. A Ras inhibitor tilts the balance between Rac and Rho and blocks phosphatidylinositol 3-kinase-dependent glioblastoma cell migration. Cancer Res 66: 11709-11717.
12. Holland EC. 2001. Gliomagenesis: Genetic alterations and mouse models. Nat Rev Genet 2: 120-129.
13. Fonseca C, Simoes S, Gaspar R. 2002. Paclitaxel-loaded PLGA nanoparticles: Preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release 83: 273-286.
14. Mu L, Feng SS. 2003. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J Control Release 86: 33-48.
15. Winternitz CI, Jackson JK, Oktaba AM, Burt HM. 1996. Development of a polymeric surgical paste formulation for taxol. Pharm Res 13: 368-375.
16. Fung LK, Ewend MG, Sills A, Sipos EP, Thompson R, Watts M, Colvin OM, Brem H, Saltzman WM. 1998. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res 58: 672-684.
17. Brem H, Mahaley MS, Jr., Vick NA, Black KL, Schold SC, Jr., Burger PC, Friedman AH, Ciric IS, Eller TW, Cozzens JW, Kenealy JN. 1991. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 74: 441-446.
18. Xie J, Wang CH. 2006. Electrospun micro- and nanofibers for sustained delivery of paclitaxel to treat C6 glioma in vitro. Pharm Res 23: 1817-1826.
19. Ranganath SH, Wang CH. 2008. Biodegradable microfiber implants delivering paclitaxel for post-surgical chemotherapy against malignant glioma. Biomaterials 29: 2996-3003.
20. Kraitzer A, Ofek L, Schreiber R, Zilberman M. 2008. Long-term in vitro study of paclitaxel-eluting bioresorbable core/shell fiber structures. J Control Release 126: 139-148.
21. Haklai R, Weisz MG, Elad G, Paz A, Marciano D, Egozi Y, Ben-Baruch G, Kloog Y. 1998. Dislodgment and accelerated degradation of Ras. Biochemistry 37: 1306-1314.
22. Zundelevich A, Elad-Sfadia G, Haklai R, Kloog Y. 2007. Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid). Mol Cancer Ther 6: 1765-1773.
23. Herrmann C, Martin GA, Wittinghofer A. 1995. Quantitative analysis of the complex between p21ras and the Ras-binding domain of the human Raf-1 protein kinase. J Biol Chem 270: 2901-2905.
24. Elad-Sfadia G, Haklai R, Ballan E, Gabius HJ, Kloog Y. 2002. Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase. J Biol Chem 277: 37169-37175.
25. Siepman J, Gopferich A. 2001. Mathematical modeling of bioerodible polymeric drug delivery systems. Adv Drug Deliv Rev 48: 229-247.
26. Ranade SV, Miller KM, Richard RE, Chan AK, Allen MJ, Helmus MN. 2004. Physical characterization of controlled release of paclitaxel from the TAXUS Express2 drug-eluting stent. J Biomed Mater Res A 71: 625-634.
27. Chitkara D, Shikanov A, Kumar N, Domb AJ. 2006. Biodegradable injectable in situ depot-forming drug delivery systems. Macromol Biosci 6: 977-990.
28. Shikanov A, Vaisman B, Krasko MY, Nyska A, Domb AJ. 2004. Poly(sebacic acid-co-ricinoleic acid) biodegradable carrier for paclitaxel: In vitro release and in vivo toxicity. J Biomed Mater Res A 69: 47-54.
29. Blum R, Jacob-Hirsch J, Amariglio N, Rechavi G, Kloog Y. 2005. Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. Cancer Res 65: 999-1006.
30. Blum R, Jacob-Hirsch J, Rechavi G, Kloog Y. 2006. Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis. Mol Cancer Ther 5: 2337-2347.
31. Rotblat B, Ehrlich M, Haklai R, Kloog Y. 2008. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: A potential treatment for cancer. Methods Enzymol 439: 467-489.
32. Marciano D, Ben-Baruch G, Marom M, Egozi Y, Haklai R, Kloog Y. 1995. Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras-dependent cell growth. J Med Chem 38: 1267-1272.